Clinical trials: High-grade B-cell Lymphoma (HGBL)
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
- Conditions
- Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL)
- Trial name
- TC011 (NCT07473167)
- Testing
- TC011
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- TICAROS Co., Ltd.
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Relapsed Lymphoma
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2…
- Conditions
- Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma
- Trial name
- NCT01742988
- Testing
- fimepinostat, Rituximab, venetoclax
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Curis, Inc.
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone chemotherapy consisting of R-CHOP or polatuzumab vedotin-RCHP for younger patients…
- Trial name
- COALITION (NCT04914741)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 15 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04594642
- Testing
- AZD0486 IV
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year…
- Conditions
- Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma
- Trial name
- NCT05050630
- Testing
- TR2-ICE
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Lymphoma, High-Grade
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)
Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-BL-04 with and without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed patients with High-Grade B-cell Lymphoma…
- Trial name
- NCT03479918
- Testing
- R-DA-EPOCH-21, R-BL-M-04, R-DA-EPOCH-21 + auto-SCT
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Elena N.Parovichnikova
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL)
- Trial name
- NCT06014762
- Testing
- P-CD19CD20-ALLO1, Rimiducid
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Poseida Therapeutics, Inc.
Non Hodgkin Lymphoma, Lymphoma, B-Cell
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
The prognosis of patients with "high-grade B cell lymphoma with cellular myelocytomatosis (MYC) and B cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 (BCL6) rearrangements" (double hit (DH)/triple hit (TH)-HGBL) with…
- Conditions
- Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma, MYC Translocation
- Trial name
- HO152 (NCT03620578)
- Testing
- DA-EPOCH-R followed by Nivolumab
- Where
- 24 sites in Belgium, Netherlands
- Volunteers
- 97 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL)
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
- Trial name
- CLEAR (NCT07197307)
- Testing
- Loncastuximab Tesirine and Epcoritamab
- Where
- 34 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Universität Münster
Large B Cell Lymphoma, LBCL
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with…
- Conditions
- Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma
- Trial name
- NCT07875413
- Testing
- Prizloncabtagene Autoleucel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- AbelZeta Inc.
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics